Medicare Part D drugs starting with B
103 drugs start with B; 41 of them are on at least 90% of 2026 Part D formularies. Part D spending was highest for Biktarvy in 2024: $3.5 billion, what plans and patients paid at the pharmacy before rebates.
Which drugs start with B?
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Bacitracin | 100% | Tier 2 | $1 million |
| Bacitracin / neomycin / polymyxin b | 99.7% | Tier 3 | $335 thousand |
| Bacitracin / polymyxin b | 99.8% | Tier 2 | $532 thousand |
| Bacitracin zinc / hydrocortisone acetate / neomycin sulfate / polymyxin b sulfate | 97.6% | Tier 3 | no 2024 match |
| Baclofen | 100% | Tier 2 | $88 million |
| Bactrim (sulfamethoxazole / trimethoprim) | under 0.1% | Tier 1 | $2 thousand |
| Bafiertam (monomethyl fumarate) | 42.6% | Tier 5 | $8 million |
| Balcoltra (ethinyl estradiol / levonorgestrel) | under 0.1% | Tier 2 | $15 thousand |
| Balsalazide disodium | 100% | Tier 4 | $19 million |
| Balversa (erdafitinib) | 100% | Tier 5 | $23 million |
| Balziva (ethinyl estradiol / norethindrone) | 85.7% | Tier 2 | $40 thousand |
| Banzel (rufinamide) | 0.4% | Tier 5 | $18 million |
| Baqsimi (glucagon) | 56.6% | Tier 3 | $22 million |
| Baraclude (entecavir) | 91.9% | Tier 5 | $3 million |
| Basaglar (insulin glargine) | 1% | Tier 3 | $665 million |
| Baxdela (delafloxacin) | 2.3% | Tier 5 | $1 million |
| Bcg, live, tice strain | 100% | Tier 1 | no 2024 match |
| Belbuca (buprenorphine) | 6.6% | Tier 3 | $160 million |
| Belsomra (suvorexant) | 58.1% | Tier 3 | $150 million |
| Benazepril hydrochloride | 100% | Tier 1 | $22 million |
| Benazepril hydrochloride / hydrochlorothiazide | 97.7% | Tier 1 | $9 million |
| Benicar (olmesartan medoxomil) | under 0.1% | Tier 1 | $14 million |
| Benicar HCT (hydrochlorothiazide / olmesartan medoxomil) | under 0.1% | Tier 1 | $6 million |
| Benlysta (belimumab) | 100% | Tier 5 | $217 million |
| Benzamycin (benzoyl peroxide / erythromycin) | under 0.1% | Tier 1 | no 2024 match |
| Benzoyl peroxide / clindamycin | 42.7% | Tier 4 | $2 million |
| Benzoyl peroxide / clindamycin phosphate | 54.3% | Tier 2 | no 2024 match |
| Benzoyl peroxide / erythromycin | 68.8% | Tier 4 | $714 thousand |
| Benztropine mesylate | 100% | Tier 2 | $24 million |
| Bepotastine besilate | 17.4% | Tier 4 | $10 million |
| Bepreve (bepotastine besilate) | 15.3% | Tier 4 | $1 million |
| Berinert (C1 esterase inhibitor, human) | 28.7% | Tier 5 | $35 million |
| Besifloxacin | 26.8% | Tier 3 | no 2024 match |
| Besivance (besifloxacin) | 55% | Tier 3 | $7 million |
| Besremi (ropeginterferon alfa-2b-njft) | 100% | Tier 5 | $81 million |
| Betaine | 94.7% | Tier 5 | no 2024 match |
| Betamethasone | 100% | Tier 2 | $33 million |
| Betamethasone / clotrimazole | 100% | Tier 2 | $39 million |
| Betamethasone dipropionate / calcipotriene | 4.4% | Tier 4 | $3 million |
| Betamethasone valerate | 7.3% | Tier 4 | $9 million |
Show the other 63 drugs
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Betaseron (interferon beta-1b) | 78% | Tier 5 | $92 million |
| Betaxolol | 94.4% | Tier 3 | no 2024 match |
| Betaxolol hydrochloride | 60.3% | Tier 3 | $2 million |
| Bethanechol chloride | 100% | Tier 2 | $11 million |
| Bethkis (tobramycin) | 1.5% | Tier 1 | no 2024 match |
| Betimol (timolol hemihydrate) | 16% | Tier 4 | $4 million |
| Betoptic S (betaxolol) | 8.1% | Tier 4 | $4 million |
| Bevespi (formoterol fumarate / glycopyrrolate) | 36.3% | Tier 3 | $66 million |
| Bexarotene | 100% | Tier 5 | $45 million |
| Bexsero (meningococcal B vaccine) | 100% | Tier 1 | $2 million |
| Beyaz (drospirenone / ethinyl estradiol / levomefolate calcium) | under 0.1% | Tier 2 | $22 thousand |
| Bicalutamide | 100% | Tier 2 | $7 million |
| Bicillin (penicillin g benzathine / penicillin g procaine) | 43.1% | Tier 4 | no 2024 match |
| Bicillin L-A (penicillin g benzathine) | 99.1% | Tier 4 | $4 million |
| Bidil (hydralazine hydrochloride / isosorbide dinitrate) | 0.5% | Tier 3 | $520 thousand |
| Bijuva (estradiol / progesterone) | 5.2% | Tier 3 | $728 thousand |
| Biktarvy (bictegravir / emtricitabine / tenofovir alafenamide) | 100% | Tier 5 | $3.5 billion |
| Bildyos (denosumab-nxxp) | 27% | Tier 4 | no 2024 match |
| Bilprevda (denosumab-nxxp) | 14.7% | Tier 5 | no 2024 match |
| Bimatoprost | 26.8% | Tier 3 | $7 million |
| Bimzelx (bimekizumab-bkzx) | 27.8% | Tier 5 | $86 million |
| Bismuth subcitrate / metronidazole / tetracycline hydrochloride | 4.4% | Tier 4 | $3 million |
| Bisoprolol fumarate | 100% | Tier 2 | $30 million |
| Bisoprolol fumarate / hydrochlorothiazide | 99.2% | Tier 1 | $17 million |
| Bivigam (immunoglobulin g, human) | 18.3% | Tier 5 | $4 million |
| Blisovi 21 Fe (ethinyl estradiol / norethindrone acetate) | 92.6% | Tier 2 | no 2024 match |
| Blisovi 24 Fe (ethinyl estradiol / norethindrone acetate) | 76.1% | Tier 2 | $40 thousand |
| Blujepa (gepotidacin) | 42.4% | Tier 3 | no 2024 match |
| Bomyntra (denosumab-bnht) | 14.1% | Tier 5 | no 2024 match |
| Bonsity (teriparatide) | 60.1% | Tier 5 | no 2024 match |
| Boostrix (Tdap vaccine) | 100% | Tier 1 | $94 million |
| Bosentan | 76.3% | Tier 5 | $20 million |
| Bosulif (bosutinib) | 100% | Tier 5 | $235 million |
| Braftovi (encorafenib) | 100% | Tier 5 | $138 million |
| Brekiya (dihydroergotamine mesylate) | 0.2% | Tier 5 | no 2024 match |
| Breo (fluticasone furoate / vilanterol) | 97.4% | Tier 3 | $1.4 billion |
| Breyna (budesonide / formoterol fumarate) | 52.2% | Tier 3 | $116 million |
| Breztri (budesonide / formoterol fumarate / glycopyrrolate) | 88.3% | Tier 3 | $1.1 billion |
| Briellyn (ethinyl estradiol / norethindrone) | 84.8% | Tier 2 | $14 thousand |
| Brilinta (ticagrelor) | 2.8% | Tier 3 | $685 million |
| Brimonidine | 0.7% | Tier 4 | no 2024 match |
| Brimonidine tartrate | 100% | Tier 1 | $98 million |
| Brimonidine tartrate / timolol | 54.6% | Tier 3 | $84 million |
| Brinsupri (brensocatib) | 13.3% | Tier 5 | no 2024 match |
| Brinzolamide | 70.3% | Tier 4 | $38 million |
| Briviact (brivaracetam) | 100% | Tier 5 | $220 million |
| Bromfenac | 46.1% | Tier 4 | $23 million |
| Bromocriptine | 100% | Tier 4 | $7 million |
| Bromsite (bromfenac) | 0.7% | Tier 3 | $1 million |
| Brukinsa (zanubrutinib) | 100% | Tier 5 | $1.7 billion |
| Bucapsol (buspirone hydrochloride) | 2.4% | Tier 5 | no 2024 match |
| Budesonide | 100% | Tier 4 | $117 million |
| Budesonide / formoterol fumarate | 52.7% | Tier 3 | $248 million |
| Bumetanide | 100% | Tier 2 | $79 million |
| Buprenorphine | 100% | Tier 2 | $127 million |
| Buprenorphine / naloxone | 100% | Tier 2 | $200 million |
| Bupropion hydrochloride | 100% | Tier 2 | $232 million |
| Buspirone hydrochloride | 100% | Tier 1 | $111 million |
| Butorphanol tartrate | 44.6% | Tier 4 | $2 million |
| BuTrans (buprenorphine) | under 0.1% | Tier 1 | $11 million |
| Bx rating | 26% | Tier 2 | no 2024 match |
| Bylvay (odevixibat) | 16.7% | Tier 5 | $6 million |
| Bystolic (nebivolol) | under 0.1% | Tier 1 | $16 million |
Source: CMS Part D formulary file, 2026 second quarter; CMS Medicare Part D Spending by Drug, 2024.
What else should you check?
- Every drug, by letterAnd the 20 that cost Medicare most
- Stand-alone drug plans for 2027Premiums and deductibles
- Part D in 2027What changes for drug plans